Spots Global Cancer Trial Database for hepatic artery embolization
Every month we try and update this database with for hepatic artery embolization cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver | NCT02110953 | Liver Metastase... Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... | irinotecan-elut... hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | NCT02088775 | Adult Primary H... Advanced Adult ... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage D Adult P... Unspecified Adu... | PET scan CT Scan hepatic artery ... | 18 Years - | Fox Chase Cancer Center | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | NCT01042041 | Hepatocellular ... Liver Cancer Localized Unres... | sorafenib tosyl... doxorubicin hyd... cisplatin mitomycin C transarterial c... hepatic artery ... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | NCT00553683 | Breast Cancer Colorectal Canc... Gastric Cancer Liver Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Pancreatic Canc... | cyclophosphamid... poly ICLC hepatic artery ... 3-dimensional c... | 18 Years - 75 Years | Rutgers, The State University of New Jersey | |
| Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE | NCT04150874 | Hepatocellular ... Liver Cancer | Lumason® | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | NCT00079027 | Liver Cancer | doxorubicin hyd... hepatic artery ... | 18 Years - | National Cancer Institute (NCI) | |
| Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | NCT01285102 | Liver Metastase... Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IV Colon ... Stage IV Rectal... | irinotecan-elut... hepatic artery ... | 18 Years - | Fox Chase Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
